Tirzepatide (Mounjaro/Zepbound) and Wegovy (semaglutide) are both GLP-1 compounds used for weight loss — but they are different molecules with different mechanisms and different clinical outcomes.
Tirzepatide and semaglutide are different molecules. Tirzepatide activates both GLP-1 and GIP receptors. Semaglutide activates only GLP-1 receptors. Wegovy is the brand name for semaglutide approved for obesity. Zepbound is the brand name for tirzepatide approved for obesity. They are in the same drug class but are not interchangeable.
| Feature | Tirzepatide (Mounjaro/Zepbound) | Wegovy (Semaglutide) |
|---|---|---|
| Active molecule | Tirzepatide | Semaglutide |
| Mechanism | Dual GLP-1 + GIP receptor agonist | GLP-1 receptor agonist only |
| Brand name (Rx) | Mounjaro (diabetes), Zepbound (obesity) | Wegovy (obesity), Ozempic (diabetes) |
| Research form | Tirzepatide peptide | Semaglutide peptide |
| Avg weight loss (Phase 3) | ~22.5% body weight (SURMOUNT-1) | ~15% body weight (STEP-1) |
| GLP-1 activity | Full GLP-1 agonist | Full GLP-1 agonist |
| GIP activity | Full GIP agonist | None |
| FDA approval year | 2022 (Mounjaro), 2023 (Zepbound) | 2021 (Wegovy) |
| Dosing frequency | Once weekly | Once weekly |
| Max approved dose | 15 mg/week | 2.4 mg/week |
| Cardiovascular outcome data | SURPASS-CVOT (2024) | SELECT trial (2023) |
No. Tirzepatide (Mounjaro/Zepbound) and Wegovy (semaglutide) are different molecules. Wegovy contains semaglutide, a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP receptor agonist. They produce similar effects but through different mechanisms, and tirzepatide has shown greater average weight loss in clinical trials.
Clinical trial data consistently shows tirzepatide produces greater average weight loss than semaglutide (Wegovy). SURMOUNT-1 showed ~22.5% body weight reduction with tirzepatide vs ~15% with semaglutide in STEP-1. However, individual responses vary, and both compounds are highly effective.
Mounjaro contains tirzepatide (dual GLP-1/GIP agonist). Wegovy contains semaglutide (GLP-1 agonist only). Mounjaro is approved for type 2 diabetes; Zepbound (same molecule) is approved for obesity. Wegovy is approved for obesity; Ozempic (same molecule) is approved for diabetes. The key mechanistic difference is GIP receptor agonism in tirzepatide.
Switching between GLP-1 compounds is a clinical decision requiring medical supervision. Both compounds require titration schedules, and cross-titration protocols differ. In research contexts, semaglutide and tirzepatide are studied as separate compounds with distinct dosing protocols.
By weight loss outcomes, tirzepatide has demonstrated superior results in clinical trials. The addition of GIP receptor agonism is believed to enhance metabolic effects beyond GLP-1 alone. However, for cardiovascular outcomes, semaglutide has more published long-term data (SELECT trial, 2023).
Pricing reflects brand and market positioning, not molecular superiority. Wegovy (semaglutide) was approved for obesity in 2021 and has established market presence. Mounjaro/Zepbound (tirzepatide) entered the obesity market in 2023. Research-grade semaglutide and tirzepatide peptides are available at significantly lower cost than branded pharmaceutical products.
Purgo Labs provides pharmaceutical-grade tirzepatide and semaglutide with third-party COAs. Use code HEALTH for 15% off.
Shop at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.